YM 202074High affinity, selective mGlu1 antagonist CAS# 299900-84-8 |
- YM155
Catalog No.:BCC2251
CAS No.:781661-94-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 299900-84-8 | SDF | Download SDF |
PubChem ID | 90488842 | Appearance | Powder |
Formula | C56H72N8O16S2 | M.Wt | 1177.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 20 mM in water and to 100 mM in DMSO | ||
Chemical Name | (E)-but-2-enedioic acid;N-cyclohexyl-7-[[2-methoxyethyl(methyl)amino]methyl]-N-methyl-[1,3]thiazolo[3,2-a]benzimidazole-2-carboxamide | ||
SMILES | CN(CCOC)CC1=CC2=C(C=C1)N=C3N2C=C(S3)C(=O)N(C)C4CCCCC4.CN(CCOC)CC1=CC2=C(C=C1)N=C3N2C=C(S3)C(=O)N(C)C4CCCCC4.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O | ||
Standard InChIKey | HABHEZNVNBKOQJ-VQYXCCSOSA-N | ||
Standard InChI | InChI=1S/2C22H30N4O2S.3C4H4O4/c2*1-24(11-12-28-3)14-16-9-10-18-19(13-16)26-15-20(29-22(26)23-18)21(27)25(2)17-7-5-4-6-8-17;3*5-3(6)1-2-4(7)8/h2*9-10,13,15,17H,4-8,11-12,14H2,1-3H3;3*1-2H,(H,5,6)(H,7,8)/b;;3*2-1+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | High affinity, selective metabotropic glutamate receptor type 1 (mGlu1) antagonist. Binds an allosteric site of the rat mGlu1 receptor with a Ki of 4.8 nM. Inhibits mGlu1-mediated inositol phosphates production (IC50 = 8.6 nM in rat cerebellar granule cells). Neuroprotective in vivo. |
YM 202074 Dilution Calculator
YM 202074 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 0.8494 mL | 4.247 mL | 8.494 mL | 16.988 mL | 21.235 mL |
5 mM | 0.1699 mL | 0.8494 mL | 1.6988 mL | 3.3976 mL | 4.247 mL |
10 mM | 0.0849 mL | 0.4247 mL | 0.8494 mL | 1.6988 mL | 2.1235 mL |
50 mM | 0.017 mL | 0.0849 mL | 0.1699 mL | 0.3398 mL | 0.4247 mL |
100 mM | 0.0085 mL | 0.0425 mL | 0.0849 mL | 0.1699 mL | 0.2124 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 1,3,5-Trihydroxy-4-(3-hydroxy-3-methylbutyl)xanthone
Catalog No.:BCN1462
CAS No.:299895-11-7
- NKY 80
Catalog No.:BCC8003
CAS No.:299442-43-6
- NPS ALX Compound 4a dihydrochloride
Catalog No.:BCC7629
CAS No.:299433-10-6
- 5,6-Dimethyl-2-Benzothiazolamine
Catalog No.:BCC8723
CAS No.:29927-08-0
- Ro 20-1724
Catalog No.:BCC6638
CAS No.:29925-17-5
- 7-Hydroxy-6-methoxy-3-prenylcoumarin
Catalog No.:BCN5207
CAS No.:299159-90-3
- Eledoisin-Related Peptide
Catalog No.:BCC5849
CAS No.:2990-43-4
- Sparteine sulfate pentahydrate
Catalog No.:BCN1267
CAS No.:299-39-8
- Astringin
Catalog No.:BCN3412
CAS No.:29884-49-9
- Amygdalin
Catalog No.:BCN5206
CAS No.:29883-15-6
- Ro 67-7476
Catalog No.:BCC6145
CAS No.:298690-60-5
- Pirenzepine dihydrochloride
Catalog No.:BCC6923
CAS No.:29868-97-1
- Arecoline hydrobromide
Catalog No.:BCN2913
CAS No.:300-08-3
- H-Tyr(3,5-I2)-OH
Catalog No.:BCC3263
CAS No.:300-39-0
- Hypotaurine
Catalog No.:BCN1749
CAS No.:300-84-5
- Isoline
Catalog No.:BCN2063
CAS No.:30000-36-3
- HEAT hydrochloride
Catalog No.:BCC6683
CAS No.:30007-39-7
- Diphyllin O-glucoside
Catalog No.:BCN8065
CAS No.:30021-77-3
- Ro 28-1675
Catalog No.:BCC4124
CAS No.:300353-13-3
- Boc-Asn-ol
Catalog No.:BCC2587
CAS No.:30044-67-8
- Dehydrocorydalin
Catalog No.:BCN2474
CAS No.:30045-16-0
- SKF 77434 hydrobromide
Catalog No.:BCC7144
CAS No.:300561-58-4
- HMBA Linker
Catalog No.:BCC2831
CAS No.:3006-96-0
- BMS 309403
Catalog No.:BCC8046
CAS No.:300657-03-8
Radiosynthesis and evaluation of [11C]YM-202074 as a PET ligand for imaging the metabotropic glutamate receptor type 1.[Pubmed:20610166]
Nucl Med Biol. 2010 Jul;37(5):615-24.
INTRODUCTION: Developing positron emission tomography (PET) ligands for imaging metabotropic glutamate receptor type 1 (mGluR1) is important for studying its role in the central nervous system. N-cyclohexyl-6-{[N-(2-methoxyethyl)-N-methylamino]methyl}-N-methylthiazolo[3,2-a] benzimidazole-2-carboxamide (YM-202074) exhibited high binding affinity for mGluR1 (K(i)=4.8 nM), and selectivity over other mGluRs in vitro. The purpose of this study was to label YM-202074 with carbon-11 and to evaluate in vitro and in vivo characteristics of [(11)C]YM-202074 as a PET ligand for mGluR1 in rodents. METHODS: [(11)C]YM-202074 was synthesized by N-[(11)C]methylation of its desmethyl precursor with [(11)C]methyl iodide. The in vitro and in vivo brain regional distributions were determined in rats using autoradiography and PET, respectively. RESULTS: [(11)C]YM-202074 (262-630 MBq, n=5) was obtained with radiochemical purity of >98% and specific activity of 27-52 GBq/mumol at the end of synthesis, starting from [(11)C]CO(2) of 19.3-21.5 GBq. In vitro autoradiographic results showed that the high specific binding of [(11)C]YM-202074 for mGluR1 was presented in the cerebellum, thalamus and hippocampus, which are known as mGluR1-rich regions. In ex vivo autoradiography and PET studies, the radioligand was specifically distributed in the cerebellum, although the uptake was low. Furthermore, the regional distribution was fairly uniform in the whole brain by pretreatment with JNJ16259685 (a mGluR1 antagonist). However, radiometabolite(s) was detected in the brain. CONCLUSIONS: From these results, especially considering the low brain uptake and the influx of radiometabolite(s) into brain, [(11)C]YM-202074 may not be a useful PET ligand for in vivo imaging of mGluR1 in the brain.
Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models.[Pubmed:18164695]
Brain Res. 2008 Jan 29;1191:168-79.
We describe in vitro properties and in vivo neuroprotective effects of a newly synthesized, high-affinity, selective allosteric metabotropic glutamate receptor type 1 (mGluR(1)) antagonist, N-cyclohexyl-6-{[(2-methoxyethyl)(methyl)amino]methyl}-N-methylthiazolo[3,2-a]ben zimidazole-2-carboxamide (YM-202074). YM-202074 bound an allosteric site of rat mGluR(1) with a K(i) value of 4.8+/-0.37 nM. YM-202074 also inhibited the mGluR(1)-mediated inositol phosphates production in rat cerebellar granule cells with an IC(50) value of 8.6+/-0.9 nM, while showing selectivity over mGluR(2-7). When YM-202074 was infused intravenously at an initial dose of 20 mg/kg/h for 0.5 h followed by a dose of 5 mg/kg/h for 7.5 h, the free concentration of YM-202074 in the brain rapidly (<12 min) reached approximately 0.3 microM, reaching a steady-state phase within 1.5 h. We first treated rats such that they developed transient middle cerebral artery (MCA) occlusion. Results clearly demonstrate a dose-dependent improvement of neurological deficit and reduction of the infarct volume in both the hemisphere and cortex when YM-202074 was infused intravenously immediately after occlusion at a dose of 10 or 20 mg/kg/h for 0.5 h followed by a dose of 2.5 or 5 mg/kg/h for 23.5 h, respectively. Significant neuroprotection was maintained even when the administration of drugs was delayed by up to 2 h following the onset of ischemia. Furthermore, the improvement of neurological deficit and the reduction of infarct volume were sustained for 1 week following the onset of ischemia. These results suggest that YM-202074 exhibits great potential as a novel neuroprotective agent for the treatment of stroke.
Metabotropic glutamate 1 receptor: current concepts and perspectives.[Pubmed:19112153]
Pharmacol Rev. 2008 Dec;60(4):536-81.
Almost 25 years after the first report that glutamate can activate receptors coupled to heterotrimeric G-proteins, tremendous progress has been made in the field of metabotropic glutamate receptors. Now, eight members of this family of glutamate receptors, encoded by eight different genes that share distinctive structural features have been identified. The first cloned receptor, the metabotropic glutamate (mGlu) receptor mGlu1 has probably been the most extensively studied mGlu receptor, and in many respects it represents a prototypical subtype for this family of receptors. Its biochemical, anatomical, physiological, and pharmacological characteristics have been intensely investigated. Together with subtype 5, mGlu1 receptors constitute a subgroup of receptors that couple to phospholipase C and mobilize Ca(2+) from intracellular stores. Several alternatively spliced variants of mGlu1 receptors, which differ primarily in the length of their C-terminal domain and anatomical localization, have been reported. Use of a number of genetic approaches and the recent development of selective antagonists have provided a means for clarifying the role played by this receptor in a number of neuronal systems. In this article we discuss recent advancements in the pharmacology and concepts about the intracellular transduction and pathophysiological role of mGlu1 receptors and review earlier data in view of these novel findings. The impact that this new and better understanding of the specific role of these receptors may have on novel treatment strategies for a variety of neurological and psychiatric disorders is considered.